A comparative study of the effects of a dipeptidyl peptidase-iv inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin

Diabetes Technology and Therapeutics

Volumn 15, Issue 10, 2013, Pages 810-816

  Kim, Hun Sung ^a   Shin, Jeong Ah ^a   Lee, Seung Hwan ^a   Kim, Eun Sook ^a   Cho, Jae Hyoung ^a   Son, Ho Young ^a   Yoon, Kun Ho ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTINUOUS GLUCOSE MONITORING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; OXIDATIVE STRESS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; PYRAZINES; REPUBLIC OF KOREA; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84884543767     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0038     Document Type: Article

References (35)

1. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599-622. (Pubitemid 35191625)
2. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2006;29(Suppl 1):S4-S42.
3. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472. (Pubitemid 34174577)
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412. (Pubitemid 30609442)
5. Monnier L, Colette C: Glycemic variability: should we and can we prevent it Diabetes Care 2008;31(Suppl 2):S150-S154.
6. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
7. Hirsch IB, Brownlee M: Should minimal glucose variability become the gold standard of glycemic control J Diabetes Complications 2005;19:178-181. (Pubitemid 40615551)
8. Bragd J, Adamson U, Bäcklund LB, Lins PE, Moberg E, Oskarsson P: Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade Diabetes Metab 2008;34:612-616.
9. Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1cindependentrisk factor for diabetic complications. JAMA 2006;295:1707-1782.
10. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-1596.
11. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559.
12. Nauck MA: Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124(1 Suppl):S3-S18.
13. Drab SR: Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010;30:609-624.
14. Neumiller JJ, Wood L, Campbell RK: Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-484.
15. Rizzo MR, Barbieri M, Marfella R, Paolisso G: Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35: 2076-2082.
16. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA: Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-267.
17. Owens DR, Swallow R, Dugi KA, Woerle HJ: Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28:1352-1361.
18. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167-176.
19. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002;61:186-194. (Pubitemid 34075146)
20. Yoon KH, Shin JA, Kwon HS, Lee SH, Min KW, Ahn YB, Yoo SJ, Ahn KJ, Park SW, Lee KW, Sung YA, Park TS, Kim MS, Kim YK, Nam MS, Kim HS, Park IB, Park JS, Woo JT, Son HY: Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in Korean drugna ̈ve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Diabetes Metab J 2011; 35:26-33.
21. Kim DJ, Lee MS, Kim KW, Lee MK: Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism 2001;50:590-593.
22. Arechavelata R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, Kaufman KD, Williams-Herman D, Goldstein BJ: Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, doubleblind, non-inferiority trial. Diabetes Obes Metab 2011;13: 160-168.
23. Kim HS, Shin JA, Chang JS, Cho JH, Son HY, Yoon KH: Continuous glucose monitoring: current clinical use. Diabetes Metab Res Rev 2012;28(Suppl 2):73-78.
24. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001;88:E14-E22.
25. Jansson PA: Endothelial dysfunction in insulin resistance and type2 diabetes. J Intern Med 2007;262:173-183.
26. Rask-Madsen C, King GL: Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007;3:46-56. (Pubitemid 46006612)
27. Ding H, Triggle CR: Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag 2005;1:55-71.
28. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F: Vascular effects of acute hyperglycemia in humans are reversed by l-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997;95:1783-1790. (Pubitemid 27164394)
29. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-494. (Pubitemid 37430502)
30. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-2072. (Pubitemid 35192812)
31. Kim JW, Yoon KH: Glucolipotoxicity in pancreatic b-cells. Diabetes Metab J 2011;35:444-450.
32. Mori Y, Taniguchi Y, Matsuura K, Sezaki K, Yokoyama J, Utsunomiya K: Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther 2011;13:699-703.
33. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19: 644-655.
34. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR: Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010;53:562-571.
35. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH: Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008;51: 183-190. (Pubitemid 50002199)